UBS Group’s Fusion Pharmaceuticals Inc. Common Shares FUSN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-79,609
| Closed | -$1.7M | – | 10360 |
|
|
2024
Q1 | $1.7M | Sell |
79,609
-143,483
| -64% | -$1.72M | ﹤0.01% | 4100 |
|
|
2023
Q4 | $2.14M | Buy |
223,092
+129,783
| +139% | +$631K | ﹤0.01% | 3746 |
|
|
2023
Q3 | $243K | Sell |
93,309
-651
| -0.7% | -$2.09K | ﹤0.01% | 5227 |
|
|
2023
Q2 | $439K | Buy |
93,960
+4,174
| +5% | +$18K | ﹤0.01% | 4932 |
|
|
2023
Q1 | $338K | Buy |
89,786
+27,110
| +43% | +$107K | ﹤0.01% | 4985 |
|
|
2022
Q4 | $197K | Buy |
62,676
+7,772
| +14% | +$19.3K | ﹤0.01% | 5463 |
|
|
2022
Q3 | $165K | Buy |
54,904
+34,350
| +167% | +$85.8K | ﹤0.01% | 5257 |
|
|
2022
Q2 | $51K | Sell |
20,554
-746
| -4% | -$3.43K | ﹤0.01% | 5898 |
|
|
2022
Q1 | $165K | Buy |
21,300
+21,253
| +45,219% | +$154K | ﹤0.01% | 5510 |
|
|
2021
Q4 | $0 | Sell |
47
-4,251
| -99% | -$26.5K | ﹤0.01% | 10893 |
|
|
2021
Q3 | $35K | Buy |
4,298
+473
| +12% | +$3.98K | ﹤0.01% | 6631 |
|
|
2021
Q2 | $31K | Buy |
+3,825
| New | +$32.9K | ﹤0.01% | 6898 |
|
|
2020
Q3 | – | Sell |
-5,484
| Closed | -$96K | – | 8520 |
|
|
2020
Q2 | $96K | Buy |
+5,484
| New | +$95.5K | ﹤0.01% | 5347 |
|
UBS Group's FUSN Position: Q2 2024 in Review
UBS Group sold out of Fusion Pharmaceuticals Inc. Common Shares (FUSN) in Q2 2024, closing a stake of 79,609 shares — an estimated $1.7M sold.
UBS Group first reported a position in FUSN in Q2 2020 and held it in 13 quarters. The position peaked at $2.14M in Q4 2023. 0 funds tracked by Wall St. Rank hold FUSN as of Q2 2024.
- UBS Group reported no remaining Fusion Pharmaceuticals Inc. Common Shares position as of Q2 2024 after selling out during the quarter.
- UBS Group sold 79,609 Fusion Pharmaceuticals Inc. Common Shares shares in Q2 2024, an estimated $1.7M.
- UBS Group first reported a position in Fusion Pharmaceuticals Inc. Common Shares in Q2 2020 and held it in 13 quarters.
- UBS Group's Fusion Pharmaceuticals Inc. Common Shares position peaked at $2.14M in Q4 2023.
- 0 funds tracked by Wall St. Rank held Fusion Pharmaceuticals Inc. Common Shares as of Q2 2024.
Based on UBS Group's 13F filing for Q2 2024, filed 14 Aug 2024.